| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8537314 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2018 | 22 Pages |
Abstract
Variants in CYP2D6 and CYP2C19 have already adequate support for clinical application. The development of future PGx tests should include best practices for clinical evidence development and for health economic assessment.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Chiara Fabbri, Joseph Zohar, Alessandro Serretti,